Prometic reports Phase II data for PBI-4050 in Alstrom syndrome

In September, Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) reported data from 8 patients with Alstrom syndrome in a Phase II trial showing

Read the full 223 word article

User Sign In